Open for inclusion

A Phase Ib/II randomised open label study of BGB324 in combination with pembrolizumab or dabrafenib/trametinib compared to pembrolizumab or dabrafenib/trametinib alone, in patients with advanced non-resectable (Stage IIIc) or metastatic (Stage IV) melanom

Cancer type: Melanoma

Phase: I/II

Principal Investigator: Nyakas Martha

Country: NO

Keywords: Norway, Oslo, BGB324, AXL-inhibitor

Status: Open for inclusion

Link to Clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT02872259?term=Melanoma&recrs=a&type=Intr&cntry1=EU%3ANO&rank=1